The following information is intended as a resource for journalists only and was factually correct at the time it was issued.
Follow AbbVie UK
Results from Upadacitinib Phase 3 SELECT-COMPARE Study Published in Arthritis and Rheumatology
Jul 11, 2019
Results from Upadacitinib Phase 3 SELECT-MONOTHERAPY Study Published in The Lancet
AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
RINVOQ® ▼(upadacitinib) Granted EU Marketing Authorisation for the Treatment of Eligible Adults with Moderate to Severe Active Rheumatoid Arthritis